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BACrEmCXDAL/permeability-increasing protein (BPI)
is a cationic antimicrobial protein produced by
polymorphonuclear leukocytes, that specifically
interacts with and kills Gram-negative bacteria.
BPl competes with lipopolysaccharide-binding
protein (LBP) secreted by liver cells into blood
plasma for binding to lipopolysaccharide (LPS)
and thus reduces the proinflammatory effects of
LPS. We have developed a time-resolved fluor-
oimmunoassay for BPI and measured the con-
centration of BPI in human serum and plasma
samples. The assay is based on a rabbit antibody
against recombinant BPI. This antibody specifi-
cally adheres to polymorphonuclear leukocytes
in immunostained human tissues. The difference
in the serum concentration of BPI between unse-
lected hospitalized patients with and without an
infection was statistically significant. The mean
concentration of BPI in serum samples was
28.3g/1 (range 1.64-132, S.D. 26.8, n=83). In
contrast, there was no difference between the two
groups in the BPI levels in plasma samples. For
all individuals tested, BPI levels were consistently
higher in plasma samples compared to the
matched serum samples. The mean concentration
of BPI in plasma samples was 52.3g/1 (range
0.9-403, S.D. 60.6, n=90). There was a positive
correlation between the concentration of BPI and
the white blood cell count as well as between the
BPI concentration and C-reactive protein (CRP) in
serum samples. In conclusion, the present study
demonstrates that BPI can be quantified reliably
by time-resolved fluoroimmunoassay in human
serum samples.
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Introduction
The bactericidal/permeability-increasing pro-
tein (BPI) is a cationic antimicrobial protein
produced by polymorphonuclear leukocytes. BPI
specifically interacts with and kills Gram-negative
bacteria. BPI binds to the lipopolysaccharide
(LPS) component of the outer membrane of
Gram-negative bacteria, increases membrane per-
meability to hydrophobic substances and causes
irreversible loss of bacterial cell homeostasis.1-6
BPI competes with lipopolysaccharide-binding
protein (LBP) secreted by liver cells into the
blood plasma for binding to LPS.7-m In this way
BPI reduces the proinflammatory effects of
gps.11-19
Because there is potential anti-infectious ther-
apeutic use for recombinant BPI,2-25 a sensitive
assay which can measure BPI in body fluids is
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needed. The purpose of the present study was to
develop a time-resolved fluoroimmunoassay (TR-
FIA) for the measurement of the concentration
of BPI in human serum.
Materials and Methods
Instrumentation: Time-resolved fluorescence was
measured with an Arcus fluorometer (Wallac,
Turku, Finland). The plate washer (Wellwash)
and plate shaker (Delfia Plateshake) used in the
fluoroimmunoassay were from Denley (Bill-
inghurst, England) and Wallac (Turku, Finland),
respectively. Data were handled with MultiCalc
data management software (Wallac, Turku,
Finland).
Serum and plasma samples: Serum and plasma
samples were collected from unselected hospital-
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ized patients with and without an infection (42
women and 48 men). The average age was 61
years (range 14-93 years). Samples were stored
frozen at -20C until assayed.
BPI standards: The BPI cDNA was cloned and
expressed in a Chinese hamster ovary cell line as
described elsewhere.26 BPI standards were pre-
pared from recombinant human BPI (kindly
donated by Dr Marian Marra, Incyte Pharmaceu-
ticals, Inc., Palo Alto, CA, USA) stock solution
into assay buffer (Wallac, Turku, Finland) to give
five concentrations (4.07, 9.76, 48.8, 122 and
Preparation of antibodies to recombinant
human BPL. Antiserum to recombinant BPI was
raised in a rabbit. The rabbit was immunized
four times at 3-week intervals subcutaneously
with 0.05-0.2mg of human recombinant BPI
(Incyte, Palo Alto, CA, USA) in Freund’s complete
adjuvant at the first immunization and in
Freund’s incomplete adjuvant on later occasions.
Serum was collected 2 weeks after the last
booster injection.
Labelling ofanti-BPI antibody: Protein A-purified
anti-recombinant BPI antibody was labelled with
an isothiocTanate derivative of a europium
chelate (Eu5 +-N-(/isothiocyanatobenzyl)-diethy-
1 2,3 3 lene-tri-amine-N ,N ,N ,N-tetra-acetate) by using
an Eu-labelling kit (Wallac, Turku, Finland)
according to the manufacturer’s instructions.
Time-resolved fluoroimmunoassays: For the TR-
FIA, microtitre plates were coated overnight with
protein A-purified anti-BPI antibody (25 l.tg/ml in
50mmol/1 Tris-HCl, pH 7.75/0.15mmol/1 NaC1/
0.05% NAN,, 2001.d/well) treated with three
volumes of HCl/water (125 txl of 11.6M HCl in
50ml of water) for 5 min. Coated plates were
washed two times and 25 l.tl of BPI standard (0,
4.07, 9.76, 48.8, 122 and 3051g/1) or sample
were pipetted into the wells containing 175 btl of
assay buffer. After I h incubation, with shaking, at
room temperature and washing six times, Eu-
labelled anti-BPI antibody (2.51xg/ml in assay
buffer, 200 Ixl/well) was added. The washing step
was repeated after I h and 2001al of enhance-
ment solution (Wallac, Turku, Finland) was
added. Fluorescence was measured after a
further 5 min shaking and 10 min standing.
Microtitre plates were from Eflab (Helsinki,
Finland) and assay buffer for TR-FIA was from
Wallac (Turku, Finland).
Immunostaining: Sections of formalin-fixed, par-
affin-embedded human tissues from the files of
the Department of Pathology, University of Turku
were reacted with an IgG fraction of polyclonal
rabbit anti-BPI antiserum, and the primary immu-
noreaction was localized as described pre-
viously
27 by using a Vectastain ABC kit (Vector
Laboratories, Burlinghame, CA, USA) according
to manufacturer’s instructions. The intensity of
immunostaining improved when the sections
were heated for 2 x 5 min in a microwave oven
before staining. For controls, the primary anti-
body was replaced by preimmune rabbit serum.
The sections were counterstained by haemat-
oxylin.
Statistical analysis: Student’s t-test and Pearson’s
linear regression were used for statistical analysis.
Results
The mean concentration of BPI in plasma
(n--90) was 52.31xg/1 (range 0.9-403, S.D.
60.6) and in serum samples (n 83) 28.31xg/1
(range 1.64-132, S.D. 26.8). The linear range for
the BPI standard curve was 5-500 l.tg/1 (Fig. 1).
The detection limit of the assay was 1.6 lxg/1 cor-
responding to the mean 3 S.D. of the zero
standard (blank) fluorescence counts. The differ-
ence in the serum concentration of BPI between
unselected hospitalized patients with and without
infection was statistically significant (p < 0.0001,
Fig. 2). The mean concentration of BPI in serum
samples for all measured patients was 28.3 lxg/1
(range 1.64-132, S.D. 26.8, n 83). In contrast,
there was no difference between the two groups
in plasma samples. For all individuals tested, BPI
ZBBB-
IBBB-
588-
ZBB-
1BB-
sB-
2B-
,,,I ,,,I
’"1 ’"1
5 18 ZB 58 188 ZBB 588
BPI (#g/l)
FIG. 1. The standard curve of time-resolved fluoroimmunoassay
for BPI three separate assays.
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FIG. 2. Difference in the BPI concentrations between unselected
hospitalized patients without an infection (group O, n=45) and
patients with an infection (group 1, n=38, p < 0.0001). Stu-
dent’s test was used for statistical analysis.
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FIG. 3. Linear regression with 95% confidention intervals
between blood white cell count (WBC, 109/I) and serum ;BPI
concentration (r 0.589, p < 0.0001, n 83).
FIG. 5. Immunoreaction for BPI in polymorphonuclear leukocytes
in the vascular compartment of colonic mucosa. Anti-BPI anti-
body. Avidin-biotin-peroxidase complex, haematox1in counter-
staining. Magnification 330 x.
There was a positive correlation between the
concentration of BPI in serum and the white
blood cell count (r 0.589, p < 0.0001, n-- 83)
(Fig. 3). There was also a positive correlation
between serum BPI and CRP levels (r 0.39,
p < 0.05, n 59). However, in plasma samples
there was no correlation between BPI and whim
blood cell count or CRP. Intense immunoreac-
tion was seen in polymorphonuclear leukocytes
at numerous locations, e.g. in the vascular com-
partment of kidney glomeruli (Fig. 4) and
colonic mucosa (Fig. 5). Control sections reacted
with preimmune serum were devoid of immu-
noreaction.
FIG. 4. Immunoreaction for BPI in polymorphonuclear leukocytes
in the vascular compartment of a glomerulus of human kidney.
Anti-BPI antibody. Avidin-biotin-peroxidase complex, haematoxy-
lin counterstaining. Magnification 330 x.
levels were consistently higher in plasma samples
compared to the matched serum samples. The
mean concentration of BPI in plasma samples
was 52.3 lg/1 (range 0.9-403, S.D. 60.6, n- 90).
Discussion
The present paper describes a new immu-
noassay using time-resolved fluorescence tech-
nology for measuring the concentration of BPI.
An enzyme immunoassay (ELISA) for determining
the concentration of BPI was recently developed
by White and coworkers.
28 The mean concentra-
tion of BPI in serum as measured by the ELISA
28
and the current TR-FIA are very similar (27.1 lag/1
and 28.3 btg/1, respectively). As determined by the
current TR-FIA, there was a positive correlation
between the concentration of BPI and the whim
blood cell count as well as between the serum
BPI and CRP values. A statistically significant dif-
ference was found in the serum BPI levels
between patients with and without manifest
infections by the current TR-FIA. Furthermore,
the presence of BPI in polymorphonuclear leu-
kocytes was confirmed by immunohistochemistry
in the current study. Thus, the serum concentra-
tion of BPI seems to reflect the intensity of the
inflammatory process in the body.
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The mean concentration of BPI in heparinized
plasma samples was markedly higher than that in
serum samples as determined by the current
assay. However, no correlations was found
between BPI values and whim blood cell counts
in plasma samples. Furthermore, BPI concentra-
tions varied randomly in plasma samples when
ammonium-heparin, sodium citrate and EDTA
were used as anticoagulants in preliminary tests
(data not shown). Thus, the detection of BPI in
plasma calls for further studies.
In conclusion, the concentration of BPI can be
measured reliably in human serum by time-
resolved fluoroimmunoassay.
References
1. Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P.
Cloning of a human neutrophil bactericidal protein. J Biol Chern 1989;
26: 9505-9509.
2. Ooi CE, Weiss J, Elsbach P, Frangione B, Mannion B. A 25-kDa NH2-
terminal fragment carries all the antibacterial activities of the human neu-
trophil 60-kDa bactericidal permeability-increasing protein. J Biol Cbem
1987; 262: 14891-14894.
3. Elsbach P, Weiss J. Phagocytosis of bacteria and phospholipid
degradation. Biochim Biophys Acta 1988; 947: 29-52.
4. Weiss J, Elsbach P, Shu C, Castillo J, Grinman J, Horwitz A, Theofan G.
The human bactericidal/permeability-increasing protein and a recombi-
nant NH2-terminal fragment cause killing of serum resistant gram-nega-
tive bacteria. J Clin Invest 1992; 90: 1122-1130.
5. Weiss J, Beckerdite-Quagliata S, Elsbach P. Determinants of the action of
phospholipases A2 on the envelope phospholipids of Escherichia coli. J
Biol Chem 1979; 254: 11010-11014.
6. Forst S, Weiss J, Maraganoe JM, Heinrikson RL, Elsbach P. Relation
between binding and the action of phospholipases A2 on Escherichia coli
exposed to the bactericidal/permeability-increasing protein of
neutrophils. Biochem Biophys Acta 1987; 920: 221-225.
7. Wilde CG, Seilhamer JJ, McGrogan M, et aL Bactericidal/permeability-
increasing protein and lipopolysaccharide (LPS)-binding protein. J Biol
Cem 1994; 269: 17411-17416.
8. Tobias PS, Ulevitch RJ. Lipopolysaccharide-binding-protein (LBP) and
CD14 in lipopolysaccharide-dependent macrophage activation. Immuno-
bio11993; 187: 227-232.
9. Haziot A, Tsuberi BZ, Goyert SM. Neutrophil CD14: biochemical proper-
ties and role in the secretion of tumor necrosis factor-alpha in response
to lipopolysaccharide. J Immuno11993; 150". 15556-15565.
10. Ischii Y, Wang Y, Haziot A, Del Vecchio PJ, Goyert SM, Malik AB. Lipopo-
lysaccharide-binding-protein and CD14 interaction induces tumor necro-
sis factor-alpha generation and neutrophil sequestration in lungs after
intratracheal endotoxin. Cam Res 1993; 73." 15-23.
11. Heumann D, Gallay P, Betz-Corradin S, Barras C, Baumgarmer JD,
Glauser MP. Competition between bactericidal/permeability-increasing
protein and lipopolysaccharide-binding-protein for binding to monocytes.
J Infect Dis 1993; 167: 1351-1357.
12. Dentener WA, van Asmuth EJ, Francot GJ, Marra MN, Buurman WA.
Antagonistic effects of lipopolysaccharide-binding-protein and bacter-
icidal/permeability-increasing protein on lipopolysaccharide (LPS)
induced cytokine release by mononuclear phagocytes. Competition for
binding to LPS. J Immuno11993; 151." 4258-4265.
13. Ooi CE, Weiss J, Doerfler ME, Elsbach P. Endotoxin neutralizing proper-
ties of the 25-kD N-terminal fragment and a newly isolated 30-kD C-term-
inal fragment of the 55-60 kD bactericidal/permeability-increasing protein
of human neutrophils. J Exp Med 1991; 174: 649-655.
14. Marra MN, Thornton MB, Snable JL, Wilde CG, Scott RW. Endotoxin
binding and neutralizing properties of recombinant bactericidal/perme-
ability-increasing protein and monoclonal antibodies HA-1A and E5. Crit
Care Med 1994; 22; 559-565.
15. Gazzano-Santoro H, Meszaros K, Birr C, et al. rBPI23, a recombinant
fragment of bactericidal/permeability-increasing protein and lipopoly-
saccharide-binding-protein for binding to lipopolysaccharide and gram-
negative bacteria. Infect Immun 1994; 62: 1185-1191.
16. Corradin SB, Heumann D, Gallay P, Smith J, Manel J, Glauser MP. Bacter-
icidal/permeability-increasing protein inhibits induction of macrophage
nitric oxide production by lipopolysaccharide. J Infect Dis 1994; 169:
105-111.
17. Ammons WS, Kung AH. Recombinant amino-terminal fragment of bacter-
icidal/permeability-increasing protein prevents hemodynamic responses
to endotoxin. Circ Shock 1993; 41: 176-184.
18. Kohn FR, Ammons WS, Horwitz A, Grinman L, Theofan G, Weickmann J,
Kung AH. Protective effect of a recombinant amino-terminal fragment of
bactericidal/permeability-increasing protein in experimental endotoxemia.
J Infect Dis 1993; 168: 1307-1310.
19. Meszaros K, Parent JB, Gazzano-Santoro H, eta/. A recombinant amino-
terminal fragment of bactericidal/permeability-increasing protein inhibits
the induction of leucocyte responses to lipopolysaccharide. J Leukoc Biol
1993; 54: 558-563.
20. Fisher Jr CJ, Marra MN, Palardy JE, Marchbanks CR, Scott RW, Opal SM.
Human neutrophil bactericidal/permeability-increasing protein reduces
mortality rate from endotoxin challenge: a placebo-controlled study. Crit
Care Med 1994; 22." 553-558.
21. Gazzano-Santoro H, Parent JB, Grinman L, et al. High-affinity binding of
the bactericidal/permeability-increasing protein and a recombinant
amino-terminal fragment to the lipid-A region of lipopolysaccharide.
Infect Immun 1992; 60-. 4754-4761.
22. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW. The
role of bactericidal/permeability-increasing protein as a natural inhibitor
of bacterial endotoxin. J Immuno11992; 148." 532-537.
23. Weiss J, wright G. Mobilization and function of extracellular phospholi-
pase A2 in inflammation. Adv Exp Med Bio11990; 275: 103-113.
24. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in
the acute phase reactant lipopolysaccharide-binding-protein (LBP). J Biol
Chem 1989; 264: 10867-10871.
25. Mathison J, Tobias P, Wolfson E, Ulevitch RJ. Regulatory mechanisms of
host responsiveness to endotoxin (lipopolysaccharide). Pathobiology
1991; 59: 185-188.
26. Wilde CG, Seilhamer M, McGrogan N, et al. Bactericidal/permeability-
increasing protein and lipopolysaccharide (LPS)-binding protein. J Biol
Chem 1994; 269: 17411-17416.
27. Hsu SM, Raine L, Fanger H. The use of avidin-biotin-peroxidase complex
(ABC) in immunoperoxidase techniques: a comparison between ABC
and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;
29: 577-580.
28. White ML, Ma JK, Birr CA, Trown PW, Carroll SF. Measurement of bacter-
icidal/permeability-increasing protein in human body fluids by sandwich
ELISA. JImmun Methods 1994; 167: 227-235.
ACKNOWLEDGEMENTS. The authors wish to thank Dr Marian Marra for
recombinant human BPI and Ms Virpi Myllys for immunohistochemical pre-
parations. This work was supported by Academy of Finland, the University of
Turku Foundation, and Cancer Society of Southwestern Finland.
Received 11 October 1995;
accepted in revised form 8 December 1995
50 Mediators of Inflammation Vol 5 1996